Medicare Enrolled

Dr. Raja Mudad, MD

Hematology & Oncology · Miami, FL
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
1475 NW 12TH AVE, Miami, FL 33136
3052434900
In practice since 2006 (19 years)
NPI: 1427068154 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mudad from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mudad? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mudad

Dr. Raja Mudad is a hematology & oncology specialist in Miami, FL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Mudad performed 96 Medicare services across 34 unique beneficiaries.

Between the years covered by Open Payments, Dr. Mudad received a total of $424,942 from 71 pharmaceutical and/or device companies across 988 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mudad is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ 96 Medicare services $424,942 industry payments

Medicare Practice Summary

Medicare Utilization ↗
96
Medicare services
Bottom 6% in FL for hematology & oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
34
Unique beneficiaries
$59
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min) 58 $79 $299
Office visit, established patient (10-19 min) 38 $30 $99
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$424,942
Total received (2018-2024)
Avg $60,706/year across 7 years
Top 3% in FL for hematology & oncology
71
Companies
988
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$313,140 (73.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$101,844 (24.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,958 (2.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$14,430
2023
$24,547
2022
$135,278
2021
$115,311
2020
$66,787
2019
$41,238
2018
$27,351

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$89,707
AstraZeneca Pharmaceuticals LP
$86,373
Regeneron Healthcare Solutions, Inc.
$71,219
Lilly USA, LLC
$44,128
Blueprint Medicines Corporation
$35,431
Boehringer Ingelheim Pharmaceuticals, Inc.
$19,624
Regeneron Pharmaceuticals, Inc.
$17,433
Novartis Pharmaceuticals Corporation
$12,304
Genentech USA, Inc.
$9,933
Takeda Pharmaceuticals U.S.A., Inc.
$8,067
Coherus Biosciences Inc.
$7,174
Daiichi Sankyo Inc.
$6,786
TESARO, Inc.
$3,504
GENZYME CORPORATION
$2,337
NOVARTIS PHARMACEUTICALS CORPORATION
$2,025
Bayer HealthCare Pharmaceuticals Inc.
$1,069
Foundation Medicine, Inc.
$1,000
Celgene Corporation
$869
PFIZER INC.
$754
Merck Sharp & Dohme Corporation
$723
Amgen Inc.
$550
Puma Biotechnology, Inc.
$464
Incyte Corporation
$456
EMD Serono, Inc.
$378
Astellas Pharma US Inc
$337
Janssen Biotech, Inc.
$228
Seagen Inc.
$208
ARRAY BIOPHARMA INC
$124
JAZZ PHARMACEUTICALS INC.
$112
Kyowa Kirin, Inc.
$92
Teva Pharmaceuticals USA, Inc.
$90
GlaxoSmithKline, LLC.
$88
AbbVie Inc.
$78
Pharmacyclics LLC, An AbbVie Company
$75
Exelixis Inc.
$71
Taiho Oncology, Inc.
$58
Myriad Genetic Laboratories, Inc.
$56
Dova Pharmaceuticals
$55
Rigel Pharmaceuticals, Inc.
$51
Eisai Inc.
$48
Karyopharm Therapeutics Inc.
$47
Epizyme, Inc.,
$46
Mylan Institutional Inc.
$45
Gilead Sciences, Inc.
$45
SANOFI-AVENTIS U.S. LLC
$42
Ipsen Biopharmaceuticals, Inc
$42
Jazz Pharmaceuticals Inc.
$40
Fortovia Therapeutics, Inc.
$40
Deciphera Pharmaceuticals Inc.
$38
MorphoSys, US Inc.
$37
Clovis Oncology, Inc.
$36
ABIOMED
$29
Heron Therapeutics, Inc.
$25
Mirati Therapeutics, Inc.
$24
EISAI INC.
$23
Sun Pharmaceutical Industries Inc.
$23
Merck Sharp & Dohme LLC
$22
Aveo Pharmaceuticals, Inc.
$22
TerSera Therapeutics LLC
$22
Array BioPharma Inc.
$21
Seattle Genetics, Inc.
$21
Cumberland Pharmaceuticals, Inc.
$19
PUMA BIOTECHNOLOGY, INC.
$19
Octapharma USA, Inc.
$18
Axonics, Inc.
$18
SUN PHARMACEUTICAL INDUSTRIES INC.
$18
Helsinn Therapeutics (U.S.), Inc.
$17
GE HEALTHCARE
$17
Tactile Systems Technology Inc
$16
Blue Earth Diagnostics Limited
$16
Aurobindo Pharma USA, Inc.
$15
Top 3 companies account for 58.2% of total payments
Associated products mentioned in payments ›
6 · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · Axonics · Axumin · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BYNFEZIA PEN · Bavencio · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Cinvanti · DARZALEX · Doptelet · ENHERTU · ERLEADA · EVENITY · Enhertu · Erleada · FLEXITOUCH · FOTIVDA · FOUNDATIONACT · FOUNDATIONONE · FOUNDATIONONE LIQUID · Folotyn · Fulphila · GAVRETO · GAZYVA · GILOTRIF · HERZUMA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · INREBIC · Imbruvica · Impella · JAKAFI · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LOQTORZI · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MVASI · MYLOTARG · MYRISK · NERLYNX · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OPDIVO · Ogivri · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROCRIT · PROMACTA · Padcev · Prolia · QINLOCK · Quzyttir · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rubraca · SANCUSO · SARCLISA · SOMATULINE DEPOT · Stivarga · TABRECTA · TAFINLAR · TAGRISSO · TAZVERIK · TECENTRIQ · TUKYSA · Tavalisse · Tecentriq · Udenyca · VENCLEXTA · VERZENIO · VYXEOS · Vectibix · Vitrakvi · XALKORI · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · YONSA · ZEJULA · ZEPZELCA · Zuplenz · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (74%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for hematology & oncology in FL.

Equivalent to $442,648 per 100 Medicare services performed
Looking for a hematology & oncology specialist in Miami?
Compare hematology & oncology specialists in the Miami area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
179
Per 100K population
6.7
County median income
$68,694
Nearest hospital
JACKSON HEALTH SYSTEM
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Mudad is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 3% of FL peers, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Mudad experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Mudad performed 58 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mudad receive payments from pharmaceutical companies?
Yes. Dr. Mudad received a total of $424,942 from 71 companies across 988 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mudad's costs compare to other hematology & oncology specialists in Miami?
Dr. Mudad's average Medicare payment per service is $59. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mudad) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →